Lemborexant for Cannabis Use Disorder
Key facts
- Who runs it
- University of Calgary
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 28 people, planned
- Started
- Nov 2026
- Expected to end
- Nov 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Lemborexant 10mg
- Placebo
- Brief Behavioural Intervention
- Record updated
- 22 September 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Moderate to severe Cannabis Use Disorder
- Ability to read/write in English
Who cannot take part
- Current or recent (within the past 12 weeks) participation in a clinical trial involving medication administration
- Known allergies or hypersensitivities to Lemborexant
- Narcolepsy, Complex sleep behaviors, sleep apnea, restless leg syndrome, and Periodic Limb Movement Disorder
- Moderate to severe hepatic impairment
- Past or ongoing moderate to severe psychiatric disorders
- Epilepsy or history of seizures
- Use of any Orexin-Antagonist in the past 3 months
- Currently undergoing treatment for CUD
- Any hospitalization or emergency department visit related to cannabis use
- Active suicidal ideation or serious attempt within the past 3 years
- Blood pressure over 160/95mmHg at the screening session
- Current pregnancy or nursing, trying to become pregnant, or unwilling to use acceptable method of contraception during the study
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Cannabis use disorder
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to investigate the use of Lemborexant as a treatment for moderate to severe Cannabis Use Disorder (CUD). The main questions it aims to answer are:
Read full original descriptionShow less
1. Is Lemborexant safe, feasible, and tolerable to use in the CUD population? 2. Will the use of Lemborexant for CUD help to decrease cannabis use, improve sleep, decrease cannabis withdrawal symptoms, and improve cognition?
Researchers will compare 10mg Lemborexant to placebo.
Participants will:
* Take 10mg Lemborexant (or placebo) nightly for 21 nights (treatment phase). * Wear an actigraphy watch continuously for the treatment phase. * Complete a pre-screen survey, attend an in-person screening session, 4 in-person lab visits (weekly from days 0-21), and a virtual follow-up visit 2 weeks after the treatment phase. * Complete a short daily survey for 35 days total.
The 2 groups in the trial
- Lemborexant 10mgTreatment being tested
Treatment: Lemborexant 10mg and Brief Behavioural Intervention
- PlaceboPlacebo, for comparison
Treatment: Placebo and Brief Behavioural Intervention
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Lemborexant as a Potential Pharmacotherapy for the Treatment of Cannabis Use Disorder (CUD)
- Criteria questions
- Built from NCT07802990, who can take part
- Record updated
- 22 September 2026